Investigating the effects of GSK-3β inhibition on cognitive deficits in the sub-chronic phencyclidine model for cognitive impairment associated with schizophrenia
Huiming Zhu, Ben Grayson, Inés Jimenez Pulido, Charlie Clarke, Haneul Choi, Hannah Fernandes Leonard, Jennifer Fletcher, Michael Harte · FENS Forum 2024
N-methyl-D-aspartate receptor (NMDA) antagonists, such as phencyclidine (PCP), sub-chronically (sc) administrated to rodents, can lead to robust and prolonged deficits in cognitive functions and mimic neurobiological deficits found in schizophrenia. Glycogen synthase kinase-3β (GSK-3β) inhibition has been identified as an important treatment for cognitive impairment in diverse neuropsychiatric diseases. However, whether GSK-3β inhibition rescues the cognitive deficits in a model of NMDA receptor hypofunction is unknown. This study examined the acute and sub-chronic effects of GSK-3β inhibition
ePoster · Neuroscience